Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company,
engages in developing various therapeutics for amyotrophic lateral sclerosis
(ALS) and other neurodegenerative diseases. The company's product pipeline
includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium
phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral
sclerosis. It is also developing AMX0035 for other neurodegenerative diseases.
The company was founded in 2013 and is headquartered in Cambridge,
Massachusetts.
